"1667 lits et places en médecine, chirurgie, obstétrique, soins de suite polyvalents et spécialisés, soins de longue durée et secteur d'hébergement pour personnes âgées. Établissement certifié par la Haute Autorité de Santé."

During the past decade, CHD Vendée conducted 302 clinical trials. In the 10-year time frame, 302 clinical trials started and 43 clinical trials were completed, i.e. on average, 14.2% percent of trials that started reached the finish line to date. In the past 5 years, 122 clinical trials started and 27 clinical trials were completed. i.e. 22.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHD Vendée" #1 sponsor was "Nantes University Hospital" with 64 trials, followed by "Centre Hospitalier Departemental Vendee" with 54 trials sponsored, "UNICANCER" with 28 trials sponsored, "Hoffmann-La Roche" with 21 trials sponsored and "Federation Francophone de Cancerologie Digestive" with 21 trials sponsored. Other sponsors include 261 different institutions and companies that sponsored additional 114 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHD Vendée" #1 collaborator was "Ministry of Health, France" with 12 trials as a collaborator, "Hoffmann-La Roche" with 7 trials as a collaborator, "Pfizer" with 7 trials as a collaborator, "AstraZeneca" with 6 trials as a collaborator and "UNICANCER" with 6 trials as a collaborator. Other collaborators include 202 different institutions and companies that were collaborators in the rest 165 trials.

According to Clinical.Site data, the most researched conditions in "CHD Vendée" are "Breast Cancer" (19 trials), "Multiple Myeloma" (15 trials), "Colorectal Cancer" (11 trials), "Prostate Cancer" (9 trials) and "Pancreatic Cancer" (8 trials). Many other conditions were trialed in "CHD Vendée" in a lesser frequency.

Most popular intervention types in "CHD Vendée" are "Drug" (252 trials), "Other" (90 trials), "Procedure" (40 trials), "Device" (33 trials) and "Biological" (20 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (37 trials), "Rituximab" (13 trials), "Docetaxel" (11 trials), "fluorouracil" (11 trials) and "Cyclophosphamide" (9 trials). Other intervention names were less common.

The vast majority of trials in "CHD Vendée" are 387 trials for "All" genders, 44 trials for "Female" genders and 19 trials for "Male" genders.

Currently, there are NaN active trials in "CHD Vendée". 2 are not yet recruiting, 90 are recruiting, 49 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 235 completed trials in CHD Vendée, 2 suspended trials, and 41 terminated clinical trials to date.

Out of the total trials that were conducted in CHD Vendée, 7 "Phase 1" clinical trials were conducted, 100 "Phase 2" clinical trials and 155 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 16 trials, and there were also 90 trials that are defined as “Not Applicable".

CHD Vendée has several departments that took part in Clinical trials: "CH Dptal Les Oudairies; Hematologie Oncologie" - 3 trials, "Service de médecine post-urgence, infectiologie, Site de la Roche sur Yon, CHD Vendée" - 2 trials, "Centre Hospitalier Départemental de Vendée - Unité de recherche clinique" - 2 trials